MRI-guided targeting delivery of doxorubicin with reduction-responsive lipid-polymer hybrid nanoparticles

Int J Nanomedicine. 2017 Sep 14:12:6871-6882. doi: 10.2147/IJN.S143048. eCollection 2017.

Abstract

In recent years, there has been increasing interest in developing a multifunctional nanoscale platform for cancer monitoring and chemotherapy. However, there is still a big challenge for current clinic contrast agents to improve their poor tumor selectivity and response. Herein, we report a new kind of Gd complex and folate-coated redox-sensitive lipid-polymer hybrid nanoparticle (Gd-FLPNP) for tumor-targeted magnetic resonance imaging and therapy. Gd-FLPNPs can simultaneously accomplish diagnostic imaging, and specific targeting and controlled release of doxorubicin (DOX). They exhibit good monodispersity, excellent size stability, and a well-defined core-shell structure. Paramagnetic nanoparticles based on gadolinium-diethylenetriaminepentaacetic acid-bis-cetylamine have paramagnetic properties with an approximately two-fold enhancement in the longitudinal relaxivity compared to clinical used Magnevist. For targeted and reduction-sensitive drug delivery, Gd-FLPNPs released DOX faster and enhanced cell uptake in vitro, and exhibited better antitumor effect both in vitro and in vivo.

Keywords: PLGA; contrast agents; gadolinium; redox-sensitive; tumor-targeted.

MeSH terms

  • Animals
  • Cell Line, Tumor
  • Doxorubicin / chemistry
  • Doxorubicin / pharmacology*
  • Drug Delivery Systems*
  • Endocytosis / drug effects
  • Female
  • Folic Acid / chemistry
  • Folic Acid / pharmacology
  • Humans
  • Lipids / chemistry*
  • Magnetic Resonance Imaging*
  • Mice, Inbred BALB C
  • Mice, Nude
  • Nanoparticles / chemistry*
  • Oxidation-Reduction
  • Polymers / chemistry*

Substances

  • Lipids
  • Polymers
  • Doxorubicin
  • Folic Acid